Ligand Pharmaceuticals Inc.
3911 Sorrento Valley Boulevard
Suite 110
San Diego
California
92121
United States
Tel: 858-550-7500
Website: http://www.ligand.com/
Email: investors@ligand.com
545 articles about Ligand Pharmaceuticals Inc.
-
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
3/5/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.
-
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/4/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee.
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
2/27/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates.
-
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
2/22/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
-
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
2/16/2024
Ligand Pharmaceuticals Incorporated announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.
-
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2/13/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update.
-
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
2/1/2024
Ligand Pharmaceuticals Incorporated announced that effective February 1, 2024, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 93,700 shares of its common stock, 32,750 restricted stock units and 40,000 performance stock units to two non-executive employees.
-
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
1/5/2024
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.
-
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
12/12/2023
Ligand Pharmaceuticals Incorporated hosted an Investor and Analyst Day in New York City earlier. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance.
-
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
12/6/2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023.
-
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
12/1/2023
Palvella Therapeutics, Inc. today announced the expansion of their strategic partnership to accelerate Phase 3 development of QTORIN™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
-
Ligand Reports Third Quarter 2023 Financial Results
11/8/2023
Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates.
-
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
11/1/2023
Ligand Pharmaceuticals Incorporated announced that it has acquired Tolerance Therapeutics, Inc. for $20 million in cash.
-
Ligand To Report Third Quarter 2023 Financial Results On November 8
10/25/2023
Ligand Pharmaceuticals Incorporated will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
-
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
10/18/2023
Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat.
-
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
9/27/2023
Ligand Pharmaceuticals Incorporated announced that it has closed the transaction to acquire assets of Novan, Inc. following the offer it made on July 17, 2023.
-
Ligand Appoints Martine Zimmermann to its Board of Directors
9/26/2023
Ligand Pharmaceuticals Incorporated announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director.
-
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
9/22/2023
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze ® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
-
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgAN; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
9/21/2023
Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI® in IgA nephropathy versus irbesartan.
-
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
9/18/2023
Ligand Pharmaceuticals Incorporated announced that it has entered into a merger agreement, pursuant to which its subsidiary, Pelican Technology Holdings, Inc., has become a wholly owned subsidiary of Primrose Bio, Inc. Primrose Bio is a stand-alone private company focused on synthetic biology.